Gudemez E, Turegun M, Carnevale K, Zins J, Siemionow M
Department of Orthopedics and Traumatology at Ankara Hospital, Cleveland, Ohio, USA.
Plast Reconstr Surg. 1999 Jul;104(1):161-70.
We investigated the ability of anti-ICAM-1 monoclonal antibodies to reduce endothelial cell damage by assessing microvascular permeability and microcirculatory function during the acute phase of allograft rejection. The composite rat hindlimb-cremaster muscle transplantation model was employed in three experimental groups of 18 animals each. Isograft control transplantations were performed between genetically identical Lewis (LEW, RT11) rats. Allograft transplantations were performed across a major histocompatibility barrier between Lewis-Brown-Norway (LBN, RT-11+n), and Lewis (LEW, RT11) rats. In addition, a third group of animals receiving allografts was treated with 1 mg/kg/day of anti-ICAM-1 monoclonal antibody. After 24 hours, 72 hours, and 7 days, we measured microvascular permeability, leukocyte activation, functional capillary perfusion, red blood cell velocity, vessel diameters, and endothelial edema index in six animals per each follow-up period. Endothelial cell damage was assessed by measuring graft permeability to fluorescein isothiocyanate-labeled albumin (0.2 ml/100 g body weight) with computer-aided image analysis. Mean microvascular permeability was lower in the treated allograft group than in untreated controls at all follow-up times (p<0.001). In addition, anti-ICAM-1 treatment significantly reduced the activation of sticking leukocytes at 24 and 72 hours (p<0.001) and the activation of transmigrating leukocytes at 72 hours and 7 days (p<0.05). The allografts presented a characteristic microcirculatory pattern of acute rejection as early as 24 hours after transplantation. The dysfunction of the endothelial cell barrier at all time points was indicated by significant increases in the degree of allograft macromolecular permeability and in the number of activated sticking and transmigrating leukocytes. Treatment with anti-ICAM-1 antibodies significantly reduced the surge of leukocytes in the allograft transplants and protected the endothelial barrier from the acute effects of transplantation trauma.
我们通过评估同种异体移植排斥反应急性期的微血管通透性和微循环功能,研究了抗ICAM - 1单克隆抗体减少内皮细胞损伤的能力。采用复合大鼠后肢-提睾肌移植模型,分为三个实验组,每组18只动物。同基因移植对照组在基因相同的Lewis(LEW,RT11)大鼠之间进行移植。异体移植在Lewis - Brown - Norway(LBN,RT - 11 + n)和Lewis(LEW,RT11)大鼠之间跨越主要组织相容性屏障进行。此外,第三组接受异体移植的动物用1mg/kg/天的抗ICAM - 1单克隆抗体治疗。在24小时、72小时和7天后,我们在每个随访期对6只动物测量微血管通透性、白细胞活化、功能性毛细血管灌注、红细胞速度、血管直径和内皮水肿指数。通过计算机辅助图像分析测量移植物对异硫氰酸荧光素标记白蛋白(0.2ml/100g体重)的通透性来评估内皮细胞损伤。在所有随访时间,治疗后的异体移植组平均微血管通透性均低于未治疗的对照组(p<0.001)。此外,抗ICAM - 1治疗在24小时和72小时显著降低了黏附白细胞的活化(p<0.001),在72小时和7天显著降低了迁移白细胞的活化(p<0.05)。异体移植在移植后24小时就呈现出急性排斥的特征性微循环模式。在所有时间点,异体移植大分子通透性程度以及活化的黏附白细胞和迁移白细胞数量的显著增加表明内皮细胞屏障功能障碍。抗ICAM - 1抗体治疗显著减少了异体移植中的白细胞激增,并保护内皮屏障免受移植创伤的急性影响。